Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (37)

2025

  1. Acute pulmonary embolism: A multimarker calculator to predict short-term outcomes

    European Heart Journal, Vol. 46, Núm. 45, pp. 4921-4929

  2. Left ventricular ejection fraction and benefit of tricuspid valve interventions – insights from the international TRIGISTRY

    European Journal of Heart Failure, Vol. 27, Núm. 11, pp. 2634-2643

  3. Predictors of pulmonary embolism in chronic obstructive pulmonary diseases patients admitted for worsening respiratory symptoms: An individual participant data meta-analyses

    European Journal of Internal Medicine, Vol. 131, pp. 65-70

  4. Venous thromboembolism in patients aged ≥90 years: Trends in clinical features, treatment, and outcomes—RIETE registry

    Journal of the American Geriatrics Society, Vol. 73, Núm. 4, pp. 1219-1226

2024

  1. Correction to: High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells (Scientific Reports, (2024), 14, 1, (13980), 10.1038/s41598-024-64902-y)

    Scientific Reports

  2. High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells

    Scientific Reports, Vol. 14, Núm. 1

  3. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2

    Journal of the American College of Cardiology, Vol. 84, Núm. 24, pp. 2347-2363

  4. Outpatient management of cancer-associated pulmonary embolism: A post-hoc analysis from the HOME-PE trial

    Thrombosis Research, Vol. 235, pp. 79-87

  5. Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials

    European Journal of Heart Failure, Vol. 26, Núm. 7, pp. 1608-1615

  6. Prognostic Implications of Residual Tricuspid Regurgitation Grading After Transcatheter Tricuspid Valve Repair

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 12, pp. 1485-1495

  7. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  8. Risk stratification of acute pulmonary embolism

    Presse Medicale

  9. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

    The Lancet HIV, Vol. 11, Núm. 2, pp. e75-e85

  10. Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis

    European Heart Journal, Vol. 45, Núm. 32, pp. 2933-2950

  11. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

    AIDS (London, England), Vol. 38, Núm. 7, pp. 983-991

  12. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation

    European heart journal, Vol. 45, Núm. 8, pp. 586-597

  13. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

    Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 1-7

  3. Pulmonary Embolism and Chronic Obstructive Pulmonary Disease

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 8, pp. 809-815